close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lakewood-Amedex Biotherapeutics Inc. - Common Stock (NQ:LABT)

0.3878 -0.0282 (-6.78%)
Delayed Quote Updated: 2:39 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lakewood-Amedex Biotherapeutics Inc. - Common Stock

< Previous 1 2 Next >
After-Hours Market Movers: Gainers and Decliners From Today's U.S. Session ↗
Via Chartmill
After-Hours Market Movers for Nov. 5, 2026: Gainers and Losers ↗
Via Chartmill
Most Active US Stocks for Nov. 5, 2026 ↗
Via Chartmill
News headline image
Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) announced it has completed the redemption of all remaining outstanding shares of its Series C Convertible Preferred Stock. The Company redeemed... 
Via B2i Digital
After-Hours Movers: LABT, NCPL Top Gainers; Fortinet, AUROW Top Losers ↗
Via Chartmill
Top US Stock Gainers and Losers in Today's Session ↗
Via Chartmill
Today's U.S. Session Top Movers: Small-Cap Gainers and Losers ↗
Via Chartmill
Gap-Up and Gap-Down Stocks: October 23, 2026 Session ↗
Via Chartmill
Premarket Movers: October 23, 2026 US Session ↗
Via Chartmill
News headline image
Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT) today announced the presentation of research highlighting the antimicrobial profile of Nu-3, the Company's lead clinical candidate, at IDWeek 2026.... 
Via B2i Digital
News headline image
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) today announced positive preclinical data in urinary tract infection (UTI) and pulmonary infection indications in animal models treated with... 
Via B2i Digital
News headline image
Diabetes Cell Therapy Enters a New Era as Billion-Dollar Market Opportunity Takes Shape
From Insulin Management To Cell Replacement: The Diabetes Revolution Is Accelerating New York, NY – October 7, 2026 – Diabetes cell therapy is moving into a very different phase. For years, the idea of... 
Via FinancialNewsMedia
News headline image
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) today announced that CEO Kelvin Cooper, Ph.D., will participate in three upcoming industry conferences. 
Via B2i Digital
News headline image
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) announced positive Minimum Inhibitory Concentration (MIC) data from recent clinical isolates for its lead clinical candidate, Nu-3. 
Via B2i Digital
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Inc. today announced that the first patient has been dosed in its Phase 2a clinical trial evaluating Nu-3 for the treatment of patients with mildly infected diabetic... 
Via B2i Digital
News headline image
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
Lakewood-Amedex Biotherapeutics Inc. today announced that Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics, has issued a Letter to Shareholders highlighting the... 
Via B2i Digital
Topics Intellectual Property
News headline image
Lakewood-Amedex announces IRB approval and clinical site readiness for the Phase 2a trial of Nu-3
Lakewood-Amedex received IRB approvals and confirmed site readiness to begin its Phase 2a trial of Nu-3 for iDFU. 
Via B2i Digital
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. Lakewood-Amedex... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market session. The company's market cap stands at $5.4 million. Alamar Biosciences (NASDAQ:ALMR) stock rose 7.4%... 
Via Benzinga
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Derivatives
News headline image
Tech Stocks LABT, ANY, INLF, GMGMF, ZCMD Under $2 Watch Now
Via AB Newswire
Topics Artificial Intelligence
Top movers analysis one hour before the close of the markets on 2026-07-22: top gainers and losers in today's session. ↗
Via Chartmill
Curious about the most active stocks on Wednesday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday's regular session. The company's market cap stands at $11.5 million. Lakewood-Amedex (NASDAQ:LABT) shares... 
Via Benzinga
Top movers analysis in the middle of the day on 2026-07-22: top gainers and losers in today's session. ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.